ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics (ARQT) stays bullish above its 200‑day MA; investors await Q3 2026 results on Nov 4 to gauge growth in immuno‑dermatology.

Arcutis Biotherapeutics stock dipped 2.9% to $32.20, trading $53.8 M, yet YTD gains hit 14.7% and a 200‑day MA sits at $25.12, signaling long‑term upside.

Arcutis Biotherapeutics (ARQT) jumps 2.92% to $31.87, rallying 26% in a month and breaking a 52‑week high of $33.30—explore its biopharma momentum.